Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects

Claudia Devito, Jorma Hinkula, Rupert Kaul, Joshua Kimani, Peter Kiama, Lucia Lopalco, Claudia Barass, Stefania Piconi, Daria Trabattoni, Job J. Bwayo, Francis Plummer, Mario Clerici, Kristina Broliden

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

There is an urgent need for a universally effective HIV-1 vaccine, but whether a vaccine will be able to protect against HIV-1 of different clades is a significant concern. IgA from HIV-1-exposed, persistently seronegative (HEPS) subjects has been shown to neutralize HIV-1 and to block epithelial HIV-1 transcytosis, and it may target novel HIV-1 epitopes. We have tested the ability of plasma and mucosal IgA purified from HEPS subjects to neutralize HIV-1 primary isolates of different viral clades and phenotypes. IgA from two groups of HEPS subjects was tested: sex workers from Nairobi, Kenya, where clades A and D predominate, and the heterosexual partners of individuals infected by clade B virus. HIV-1-infected and low-risk uninfected individuals were included as controls. IgA purified from the blood, genital tract, and saliva of most HEPS sex workers demonstrated significant crossclade HIV-1 neutralization, whereas a more clade-restricted pattern of neutralization was found in partners of clade B-infected individuals. IgA purified from HIV-1-infected individuals also mediated cross-clade neutralization, whereas IgA from uninfected controls lacked neutralizing activity. In conclusion, mucosal and plasma IgA from HEPS subjects neutralizes HIV-1 of different clades. This ability to induce HIV-1-specific systemic and mucosal IgA may be an important feature of an effective prophylactic HIV-1 vaccine.

Original languageEnglish
Pages (from-to)413-420
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume30
Issue number4
Publication statusPublished - Aug 1 2002

Fingerprint

Immunoglobulin A
HIV-1
AIDS Vaccines
Sex Workers
Aptitude
Transcytosis
Cercopithecine Herpesvirus 1
Kenya
Heterosexuality
Saliva
Epitopes

Keywords

  • Exposed
  • HIV-1 cross-clade
  • IgA
  • Neutralization
  • Uninfected

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. / Devito, Claudia; Hinkula, Jorma; Kaul, Rupert; Kimani, Joshua; Kiama, Peter; Lopalco, Lucia; Barass, Claudia; Piconi, Stefania; Trabattoni, Daria; Bwayo, Job J.; Plummer, Francis; Clerici, Mario; Broliden, Kristina.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 30, No. 4, 01.08.2002, p. 413-420.

Research output: Contribution to journalArticle

Devito, C, Hinkula, J, Kaul, R, Kimani, J, Kiama, P, Lopalco, L, Barass, C, Piconi, S, Trabattoni, D, Bwayo, JJ, Plummer, F, Clerici, M & Broliden, K 2002, 'Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects', Journal of Acquired Immune Deficiency Syndromes, vol. 30, no. 4, pp. 413-420.
Devito, Claudia ; Hinkula, Jorma ; Kaul, Rupert ; Kimani, Joshua ; Kiama, Peter ; Lopalco, Lucia ; Barass, Claudia ; Piconi, Stefania ; Trabattoni, Daria ; Bwayo, Job J. ; Plummer, Francis ; Clerici, Mario ; Broliden, Kristina. / Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. In: Journal of Acquired Immune Deficiency Syndromes. 2002 ; Vol. 30, No. 4. pp. 413-420.
@article{42931a2866a54d368a4aa5b87151b684,
title = "Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects",
abstract = "There is an urgent need for a universally effective HIV-1 vaccine, but whether a vaccine will be able to protect against HIV-1 of different clades is a significant concern. IgA from HIV-1-exposed, persistently seronegative (HEPS) subjects has been shown to neutralize HIV-1 and to block epithelial HIV-1 transcytosis, and it may target novel HIV-1 epitopes. We have tested the ability of plasma and mucosal IgA purified from HEPS subjects to neutralize HIV-1 primary isolates of different viral clades and phenotypes. IgA from two groups of HEPS subjects was tested: sex workers from Nairobi, Kenya, where clades A and D predominate, and the heterosexual partners of individuals infected by clade B virus. HIV-1-infected and low-risk uninfected individuals were included as controls. IgA purified from the blood, genital tract, and saliva of most HEPS sex workers demonstrated significant crossclade HIV-1 neutralization, whereas a more clade-restricted pattern of neutralization was found in partners of clade B-infected individuals. IgA purified from HIV-1-infected individuals also mediated cross-clade neutralization, whereas IgA from uninfected controls lacked neutralizing activity. In conclusion, mucosal and plasma IgA from HEPS subjects neutralizes HIV-1 of different clades. This ability to induce HIV-1-specific systemic and mucosal IgA may be an important feature of an effective prophylactic HIV-1 vaccine.",
keywords = "Exposed, HIV-1 cross-clade, IgA, Neutralization, Uninfected",
author = "Claudia Devito and Jorma Hinkula and Rupert Kaul and Joshua Kimani and Peter Kiama and Lucia Lopalco and Claudia Barass and Stefania Piconi and Daria Trabattoni and Bwayo, {Job J.} and Francis Plummer and Mario Clerici and Kristina Broliden",
year = "2002",
month = "8",
day = "1",
language = "English",
volume = "30",
pages = "413--420",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects

AU - Devito, Claudia

AU - Hinkula, Jorma

AU - Kaul, Rupert

AU - Kimani, Joshua

AU - Kiama, Peter

AU - Lopalco, Lucia

AU - Barass, Claudia

AU - Piconi, Stefania

AU - Trabattoni, Daria

AU - Bwayo, Job J.

AU - Plummer, Francis

AU - Clerici, Mario

AU - Broliden, Kristina

PY - 2002/8/1

Y1 - 2002/8/1

N2 - There is an urgent need for a universally effective HIV-1 vaccine, but whether a vaccine will be able to protect against HIV-1 of different clades is a significant concern. IgA from HIV-1-exposed, persistently seronegative (HEPS) subjects has been shown to neutralize HIV-1 and to block epithelial HIV-1 transcytosis, and it may target novel HIV-1 epitopes. We have tested the ability of plasma and mucosal IgA purified from HEPS subjects to neutralize HIV-1 primary isolates of different viral clades and phenotypes. IgA from two groups of HEPS subjects was tested: sex workers from Nairobi, Kenya, where clades A and D predominate, and the heterosexual partners of individuals infected by clade B virus. HIV-1-infected and low-risk uninfected individuals were included as controls. IgA purified from the blood, genital tract, and saliva of most HEPS sex workers demonstrated significant crossclade HIV-1 neutralization, whereas a more clade-restricted pattern of neutralization was found in partners of clade B-infected individuals. IgA purified from HIV-1-infected individuals also mediated cross-clade neutralization, whereas IgA from uninfected controls lacked neutralizing activity. In conclusion, mucosal and plasma IgA from HEPS subjects neutralizes HIV-1 of different clades. This ability to induce HIV-1-specific systemic and mucosal IgA may be an important feature of an effective prophylactic HIV-1 vaccine.

AB - There is an urgent need for a universally effective HIV-1 vaccine, but whether a vaccine will be able to protect against HIV-1 of different clades is a significant concern. IgA from HIV-1-exposed, persistently seronegative (HEPS) subjects has been shown to neutralize HIV-1 and to block epithelial HIV-1 transcytosis, and it may target novel HIV-1 epitopes. We have tested the ability of plasma and mucosal IgA purified from HEPS subjects to neutralize HIV-1 primary isolates of different viral clades and phenotypes. IgA from two groups of HEPS subjects was tested: sex workers from Nairobi, Kenya, where clades A and D predominate, and the heterosexual partners of individuals infected by clade B virus. HIV-1-infected and low-risk uninfected individuals were included as controls. IgA purified from the blood, genital tract, and saliva of most HEPS sex workers demonstrated significant crossclade HIV-1 neutralization, whereas a more clade-restricted pattern of neutralization was found in partners of clade B-infected individuals. IgA purified from HIV-1-infected individuals also mediated cross-clade neutralization, whereas IgA from uninfected controls lacked neutralizing activity. In conclusion, mucosal and plasma IgA from HEPS subjects neutralizes HIV-1 of different clades. This ability to induce HIV-1-specific systemic and mucosal IgA may be an important feature of an effective prophylactic HIV-1 vaccine.

KW - Exposed

KW - HIV-1 cross-clade

KW - IgA

KW - Neutralization

KW - Uninfected

UR - http://www.scopus.com/inward/record.url?scp=0036682591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036682591&partnerID=8YFLogxK

M3 - Article

C2 - 12138348

AN - SCOPUS:0036682591

VL - 30

SP - 413

EP - 420

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -